LivaNova PLC (NASDAQ: LIVN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
How stimulating the body's largest nerve may relieve severe depression [CNN]
For those with treatment-resistant depression, vagus nerve stimulation may be an answer, studies suggest [CNN]
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression [Yahoo! Finance]
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression